Baishan

Researchers are evaluating SYS6040 for injection in a first-in-human Phase I study involving participants with advanced solid tumors, including small cell lung cancer. The study aims to assess the safety, tolerability, how the drug moves through the body, and early signs of effectiveness when used alone in this population. The study is divided into two phases: a dose escalation phase with backfill (Phase Ia) and a cohort expansion phase (Phase Ib).